Researchers have developed a new method for triggering and imaging seizures in epilepsy patients, offering physicians the ability to collect real-time data to tailor epilepsy surgery.
FDA approves Vertex and CRISPR’s Casgevy as first CRISPR-edited therapy for beta-thalassemia
The FDA has approved Vertex Pharmaceuticals and CRISPR Therapeutics’ Casgevy to treat beta-thalassemia, Vertex said Tuesday, making it the first-ever CRISPR-edited therapy for the rare